Tongshang & Tongshang HK jointly represented Luzhu Biotech in its HK IPO
On 8 May 2023, Eric Chow & Co. in Association with Commerce & Finance Law Offices (“Tongshang Hong Kong”), together with our PRC office, Commerce & Finance Law Offices (“Tongshang”), jointly represented Beijing Luzhu Biotechnology Co., Ltd. (“Luzhu Biotech”, Stock Code: 02480.HK) in its listing and global offering of H shares on the Main Board of the Hong Kong Stock Exchange, with a market capitlisation of more than HK$6.6 billion at the time of listing. This transaction marks the first initial public offering under Chapter 18A of the Hong Kong Listing Rules in 2023.
Luzhu Biotech is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases.
Luzhu Biotech’s listing is yet another project completed by the collaboration between Tongshang and Tongshang Hong Kong acting as the issuer’s PRC and Hong Kong legal advisers, respectively, where we proudly provided “one-stop shop” comprehensive and high quality PRC and Hong Kong legal services.
Tongshang Hong Kong team was led by Managing Partner Eric Chow, Partners Clement Jiang and Brandon Chow. Other team members include Senior Associate Winnie Tang, Associates Lawrence Tam and Angela Ng, and supported by Legal Assistant Yunsi Xie.